[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","ego7v1terb2qmdzqklogstpmu","revision",2,"title","Ascentage Pharma 2022 RSU 计划受托人购股公告","originalTitle","6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)","summary","Ascentage Pharma 于 2026 年 10 月 22 日在香港联交所公告，受托人依据 2022 年 RSU 计划进行股份回购。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-22T20:44:03.000Z","discoveredAt","2026-10-23T00:44:21.385Z","timelineAt","category","tip","tags",[81,82],"stockSymbols",[80],"score",12,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fRF4LiShlTH0",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","c86c09e6-70fd-49b2-b44e-e8f4cc01a66e","Ascentage Pharma 2022 RSU 计划购股事件",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,\nD.C. 20549

Form\n6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into\nEnglish)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual\nreports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form\n40-F ☐

On\nOctober 22, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) posted an announcement\non the Hong Kong Stock Exchange entitled, “PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME” . A copy\nof the announcement is furnished as Exhibit 99.1 to this Report.

INDEX TO EXHIBITS

\n \n \n \n \n \n \n \n \n

Exhibit \n Number		Exhibit Title
99.1		Announcement dated October 22, 2026

SIGNATURE

Pursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto\nduly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	ASCENTAGE PHARMA GROUP INTERNATIONAL

Date: October 22, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

","zhKind","complete","AAPG","政策与监管","回购","aihot","/items/ego7v1terb2qmdzqklogstpmu","https://www.sec.gov/Archives/edgar/data/2023311/000121390026111727/0001213900-26-111727-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792972800&sig=9d173b888aad17ec","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792972800&sig=997f44534d647b46 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792972800&sig=923979fb4a1845f5 96w","changelogVersion","2026-10-01T08:00"]